February 9, 2023
A single oral dose of the antibiotic azithromycin can reduce the risk of postpartum sepsis and death among women who deliver vaginally by one-third, according to a large multi-country clinical trial funded by the National Institutes of Health. Only 1.6% of women in the study who received azithromycin during labor developed sepsis or died within six weeks after delivery, compared to 2.4% of those who received placebo. Azithromycin did not reduce the risk of stillbirth, newborn sepsis or newborn death.
February 3, 2023
Our environment and experiences over the first 1,000 days of life have an enormous influence on our growing brain and long-term wellbeing, said Dr. Laura Stroud at the annual Stephen E. Straus Distinguished Lecture in the Science of Complementary Therapies.
February 2, 2023
Leaders from the National Institutes of Health and partner organizations outline NIH’s COVID-19 research response in a policy forum(link is external) in the journal Science. The authors also reflect on crucial lessons learned that will inform the public health research response to future pandemics. The authors emphasize that by building on decades of basic and applied research and convening all sectors in highly collaborative partnerships, the biomedical research community was able to quickly develop vaccines, therapeutics, and diagnostics in response to the COVID-19 pandemic.
Lessons learned from the NIH-led research response to COVID-19
February 1, 2023
Researchers funded by the National Institutes of Health have developed a new method to process MRI scans to reveal the distinct compartments of the placenta, take measurements of oxygen levels in each region and determine if there are malformations in blood vessels (i.e., placental lesions). Obtaining this level of detail is currently not possible using standard MRI analysis methods. The small study was supported by NIH’s Human Placenta Project, which is led by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
New MRI method provides detailed view of the placenta during pregnancy
February 1, 2023
OmniVis, which focuses on the speed, accuracy and economics of pathogen detection, has received $100,000 from the Purdue Ag-Celerator, an agriculture innovation fund.
Purdue News: Ag-Celerator fund invests $100,000 in pathogen detection company
January 31, 2023
Please join us on Friday, February 17, 2023 for the Indiana CTSI Winter Retreat, held on the campus of Purdue University. There will also be a virtual retreat option for those who cannot attend in person.
Indiana Clinical and Translational Sciences, Women’s Global Health Institute’s winter retreat to be held at Purdue on Feb. 17
January 25, 2023
Adults living in rural areas of the United States have a 19% higher risk of developing heart failure compared to their urban counterparts, and Black men living in rural areas have an especially higher risk – 34%, according to a large observational study supported by the National Institutes of Health.
Risk of developing heart failure much higher in rural areas vs. urban
January 23, 2023
One fall by an older adult can have a ripple effect that debilitates the patient and their family. There is the initial pain and injury, but the ongoing physical and mental health issues, treatment, and steps to protect that adult from falling again can be expensive and time-consuming.
Purdue News: PURDUE HHS RESEARCHERS UNCOVER NEW FALL FACTORS FOR OLDER AMERICANS
January 20, 2023
Women’s health has evolved over the past century from an emphasis on reproductive and breast health care, or ‘‘bikini medicine,’’ to a field that is comprehensive in treating the whole patient and inclusive of sex and gender identities across the spectrum.
The Evolution of the National Centers of Excellence in Women's Health: The Time for Gender and Health Equity Has Arrived
January 19, 2023
In a phase I clinical trial of a drug combination that aims to prevent metastatic tumors from recurring in the brains of women with advanced breast cancer, 83 percent of patients developed no new brain metastases. Trial participants, who had HER2-positive breast cancer and had previously been treated with radiation or surgery to eliminate metastatic tumors in the brain, received a combination of low-dose temozolomide (TMZ) and T-DM1. Results of the phase I study, which included 12 participants who were followed for three to 34 months, appeared January 27, 2023 in Clinical Cancer Research.
First clinical trial testing a prevention for breast cancer metastasis to the brain yields encouraging results
